FDA REFORM PROVISION MANDATING STRICT ADHERENCE TO 180-DAY PMA REVIEW TIME FRAME WILL LEAD TO MORE RIGOROUS FILING REVIEWS -- ODE's RICHTER
This article was originally published in The Gray Sheet
FDA likely will raise the standard for premarket approval application filing decisions as a result of the provision in pending FDA reform legislation ordering the agency adhere to the statutory 180-day PMA review time frame, Kimber Richter, Deputy Director for Clinical and Review Policy in FDA's Office of Device Evaluation, indicated at the Oct. 21 Association of Medical Diagnostics Manufacturers annual meeting in Rockville, Maryland.
You may also be interested in...
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway